Our previous studies demonstrated that casein kinase 1α1 (CSNK1A1) was significantly upregulated in the endolymphatic sac of patients with Meniere's disease (MD). However, its specific role in the development of MD remains unclear. This study aims to investigate the effects of CSNK1A1 inhibition on alleviating hydrops, inflammation, and preserving audiovestibular function in a mouse model of endolymphatic hydrops...
No actionable change for clinical practice; CSNK1A1 is a potential therapeutic target for Meniere's disease, but findings are limited to a mouse inflammation model.
Identifying CSNK1A1 as a mediator of inner ear inflammation and endolymphatic hydrops opens a new molecular target pathway for potential Meniere's disease treatments.
- 01CSNK1A1 protein mediates inner ear inflammation and endolymphatic hydrops in a mouse LPS model.
- 02Study implicates CSNK1A1 in Meniere's disease pathogenesis for the first time.
- 03LPS (lipopolysaccharide) was used to trigger an inflammatory response mimicking Meniere's-like inner ear changes.
- 04Results are preclinical only; no human data reported.
- 05Published in Otolaryngology–Head & Neck Surgery (DOI: 10.1002/ohn.70334).
CSNK1A1 mediates inner ear inflammation and endolymphatic hydrops in a lipopolysaccharide-induced mouse model.
studysupportedCSNK1A1 is implicated in Meniere's disease pathogenesis.
studypartially supported- PMID
- 42398501
- DOI
- 10.1002/ohn.70334.
- Journal
- Otolaryngology–Head & Neck Surgery
- Publication type
- research_article
- Evidence level
- 4
- Population
- Adult mice with LPS-induced inner ear inflammation
- Intervention
- Lipopolysaccharide (LPS)-induced inner ear inflammation with CSNK1A1 activity analysis
Primary outcomes
Inner ear inflammation levels; Endolymphatic hydrops formation; CSNK1A1 expression and activity